Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, the availability, for in-office use, of Fortisite™ (compounded Tobramycin 1.5% + Vancomycin 5%) from its FDA‑registered and FDA‑inspected ImprimisRx® 503B outsourcing facility.
Fortisite formulations are patent-pending high-concentration, refrigeration-stable, fortified antibiotic formulations, in solution.
The availability of Fortisite for in-office use represents the first time eyecare professionals have been able to stock a fortified or high-concentration compounded antibiotic formulation for the immediate treatment of patients in need.
ImprimisRx offers a robust Fortisite patient access program and a 100% replacement guarantee for any expired 503B Fortisite product, ensuring all prescribing U.S. eyecare professionals can continuously stock Fortisite formulations in their offices.
Eyecare professionals can order Fortisite online or call ImprimisRx Customer Care at (844) 446-6979.
In commenting on the announcement, Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said, “The availability of Fortisite formulations will provide eyecare professionals with new and important tools in their pharmaceutical armamentarium as they consider how to treat potentially sight-threatening infections.
Until there is an FDA-approved product to meet these needs, Fortisite formulations have the potential to become the standard of care for ophthalmology and optometry practices across the country.
“Because Fortisite is now available for in-office use from our FDA-registered 503B outsourcing facility, each bottle must strictly adhere to rigorous analytical testing protocols that are not required for locally regulated 503A compounding pharmacies.”
